WCN26-5340 Absence of Glucosuria Following SGLT2 Inhibitor Use Is Associated with a Lower Risk of Initial eGFR Decline

Read full text Summarise with VIRAT
Authors: Yi-Ching Chang, Wentao Li, Hsiu-Yin Ching, Yu-Cuyan Hong, I‐Wen Ting, Hung‐Chieh Yeh, Chin‐Chi Kuo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

An initial decline in estimated glomerular filtration rate (eGFR) greater than 10% is not uncommon following sodium–glucose cotransporter 2 inhibitor (SGLT2i) therapy and has been considered a benign or even beneficial effect in clinical trials. This initial eGFR decline is primarily attributed to glucosuria-induced natriuresis, which reduces glomerular hyperfiltration. However, in clinical practice, a subset of SGLT2i users exhibit minimal or absent glucosuria, and the clinical significance of this phenomenon remains unclear.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104476–104476
Publication date
25 March 2026
Language
EN